Sök artiklar i SveMed+

Observera: SveMed+ upphör att uppdateras!



COX-2-selektive haemmere - bivirkningsprofil i forhold til uspecifikke nonsteroide antiinflammatoriske praeparater
Engelsk titel: Selective COX-2 inhibitors - side effects in relation to non-specific non-steroidal anti-inflammatory drugs Läs online Författare: Möller Hansen J ; Schaffalitzky de Muckadell OB Språk: Dan Antal referenser: 18 Dokumenttyp: Översikt UI-nummer: 04121687

Tidskrift

Ugeskrift for Laeger 2004;166(50)4581-4 ISSN 0041-5782 E-ISSN 1603-6824 KIBs bestånd av denna tidskrift Denna tidskrift är expertgranskad (Peer-Reviewed)

Sammanfattning

COX-2 inhibitors were developed with the purpose of reducing the gastrointestinal side effects connected with the use of non-steroidal anti-inflammatory drugs (NSAIDs). COX-2 inhibitors have been demonstrated to reduce the risk of ulcers and probably also of ulcer complications as compared to non-specific NSAIDs. Patients at increased risk of peptic ulcer will probably benefit from the COX-2 inhibitors; other patients, however, can use the less expensive non-specific NSAIDs without substantial risk. Caution in using COX-2 inhibitors is recommended for some patients: those treated with low-dose aspirin, since aspirin eliminates the protective effects of COX-2 inhibitors; those with a previous bleeding ulcer, since the risk for rebleeding is relatively high during treatment with COX-2 inhibitors, as well as with non-specific NSAIDs combined with proton-pump inhibitors; and those with cardiovascular disease, since COX-2 inhibitors, as well as non-specific NSAIDs, rise the blood pressure, cause water retention, increase the risk of cardiac incompensation, and possibly increase the risk of thromboembolic events, as has been shown for rofecoxib.